Cardiology Research Analysis
June’s cardiology research advanced practice-changing therapeutics and precision diagnostics. Recency-weighted highlights prioritized new inpatient and peri-procedural strategies (oral nicorandil to prevent contrast-associated AKI in high-risk PCI; early signals for a first-in-class oral inotrope, AC01) and physiology-forward diagnostics (a CO2-based NIRS microvascular readout). Device and procedural innovations matured, including a sirolimus-eluting balloon strategy approaching routine DES at 1
Summary
June’s cardiology research advanced practice-changing therapeutics and precision diagnostics. Recency-weighted highlights prioritized new inpatient and peri-procedural strategies (oral nicorandil to prevent contrast-associated AKI in high-risk PCI; early signals for a first-in-class oral inotrope, AC01) and physiology-forward diagnostics (a CO2-based NIRS microvascular readout). Device and procedural innovations matured, including a sirolimus-eluting balloon strategy approaching routine DES at 1 year and a phase-3 demonstration that aficamten improves exercise physiology versus metoprolol in obstructive HCM. Across the month, cumulative evidence also strengthened cardiorenal foundations (finerenone across CKD), precision prevention (genotype-linked SGLT2 benefits), and physiology-guided PCI (QFR) with durable outcomes.
Selected Articles
1. Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study.
In a multicenter randomized, double-blind, placebo-controlled phase 1b/2a trial (n=58), AC01—an oral calcium-sensitizing ghrelin receptor agonist—was safe and well tolerated over 7–28 days with no tachycardia, pro-arrhythmic signals, or biomarker evidence of myocardial injury, supporting dose selection and advancement to efficacy trials.
Impact: First randomized clinical assessment of a safer outpatient-oriented oral inotrope addresses a long-standing therapeutic gap in HFrEF and de-risks phase-2/3 efficacy testing.
Clinical Implications: If efficacy is confirmed, AC01 could offer a safer oral inotropic option to support ambulatory HFrEF without traditional arrhythmic liabilities, potentially reducing hospitalization burden.
Key Findings
- AC01 was safe and well tolerated over 7–28 days with no AC01-related serious adverse events.
- No tachycardia, new tachyarrhythmias, ECG conduction abnormalities, or biomarker evidence of myocardial injury.
- Data support dose selection and progression to efficacy-focused phase-2 trials.
2. Nicorandil to Prevent Contrast-Associated Kidney Injury in High-Risk PCI.
A multicenter randomized trial (n=585) in patients with renal dysfunction undergoing PCI showed that oral nicorandil reduced CA-AKI in a dose-dependent manner: 19.8% (hydration alone) versus 10.9% (5 mg TID) and 8.7% (10 mg TID).
Impact: Demonstrates a low-cost, readily implementable peri-procedural strategy that reduces a frequent and morbid PCI complication, supporting rapid protocol adoption.
Clinical Implications: Consider peri-procedural oral nicorandil (10 mg TID) plus hydration in high-risk PCI to reduce CA-AKI while awaiting longer-term renal and clinical outcomes.
Key Findings
- Randomized 585 high-risk PCI patients with dose-stratified nicorandil vs hydration alone.
- CA-AKI incidence fell to 10.9% (5 mg TID) and 8.7% (10 mg TID) from 19.8% with hydration alone.
- A clear dose-response renoprotective effect was observed.
3. Carbon dioxide is a triple vasodilator.
Mouse mechanistic and human vascular studies show CO2 induces vasodilation via coordinated endothelial NO/sGC, EDHF (SKCa/IKCa), and myogenic K+ channels, and introduce a NIRS-CO2 time-to-intersection (TTI) metric that correlates with PAD/CAD and captures disease-related microvascular delay.
Impact: Unifies CO2-mediated vasodilation mechanisms and delivers a feasible noninvasive microvascular biomarker with translational potential for bedside assessment.
Clinical Implications: NIRS-CO2 could enable bedside profiling of integrated endothelial and myogenic microvascular function and monitor disease or therapy response; pathways nominate drug targets (NO–sGC, K+ channels, carbonic anhydrases).
Key Findings
- CO2 elicited vasodilation via endothelial NO/sGC, EDHF (SKCa/IKCa), and myogenic K+ channels.
- A NIRS-CO2 time-to-intersection (TTI) metric correlated with PAD/CAD status and detected delayed microvascular reactivity.
- Bridges basic vascular biology to a noninvasive clinical readout with diagnostic potential.
4. Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.
In a phase-3 randomized, active-controlled trial (n=175 randomized; 165 core-lab CPET), aficamten improved multiple exercise physiology endpoints versus metoprolol over 24 weeks, including better VE/VCO2 slope, higher anaerobic threshold, increased peak workload, and faster VO2 recovery; large declines in exercise capacity were less frequent.
Impact: Demonstrates superiority of a disease-specific myosin inhibitor over beta-blockade on physiologic endpoints, challenging current first-line pharmacotherapy in obstructive HCM.
Clinical Implications: Supports considering aficamten for symptomatic obstructive HCM to improve exercise capacity, with broader adoption contingent on long-term safety and hard outcomes.
Key Findings
- Improved submaximal VE/VCO2 slope (−2.8) and increased anaerobic threshold (+76 mL/min) versus metoprolol.
- Increased peak workload (+8 W) and faster VO2 recovery (−11 s); more frequent large peak VO2 gains (≥3.0 mL/kg/min: 20.5% vs 3.7%).
- Large declines in exercise capacity were less common with aficamten.
5. Sirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trial.
In a multicenter randomized trial (n=3,323) of de novo coronary lesions, a sirolimus-eluting balloon (SEB) strategy with provisional DES met the ITT noninferiority margin for 1-year target vessel failure versus routine DES (5.3% vs 4.4%; risk difference 0.91%). Bailout stenting occurred in ~20.7% and clinically driven revascularization was higher with SEB; per-protocol noninferiority was not confirmed.
Impact: Largest randomized evaluation of a prolonged-release SEB and minimal-stent approach, potentially redefining device strategy if longer-term outcomes remain acceptable.
Clinical Implications: Supports selective minimal-stent strategies to reduce permanent metal when appropriate, while emphasizing careful patient/lesion selection pending 5-year data.
Key Findings
- 1-year target vessel failure: SEB 5.3% vs routine DES 4.4% (risk difference 0.91%) meeting ITT noninferiority.
- Bailout stenting occurred in ~20.7% in the SEB arm; clinically driven revascularization was higher with SEB.
- Per-protocol analysis did not confirm noninferiority; longer-term data pending.